Opus Genetics outlines five gene therapy programs for retinal diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
June 16, 2026 4:05 PM EDTRapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027
RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months
Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers
IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics Pipeline
RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) --... More
